Format

Send to

Choose Destination
Drugs. 2019 Jan;79(1):11-20. doi: 10.1007/s40265-018-1038-8.

Recent Developments in Male Contraception.

Author information

1
Division of Metabolism, Endocrinology and Nutrition, University of Washington, 1959 NE Pacific Street, UW Mailbox 356426, Seattle, WA, 98195-6426, USA.
2
Division of Metabolism, Endocrinology and Nutrition, University of Washington, 1959 NE Pacific Street, UW Mailbox 356426, Seattle, WA, 98195-6426, USA. page@uw.edu.

Abstract

Unplanned pregnancies are an ongoing global burden, posing health and economic risks for women, children, and families. Advances in male contraception have been historically stymied by concerning failure rates, problematic side effects, and perceived market limitations. However, increased interest in reliable and reversible options for male contraception have resulted in resurgent efforts to introduce novel contraceptives for men. Hormonal male contraception relies on exogenous androgens and progestogens that suppress gonadotropin production, thereby suppressing testicular testosterone and sperm production. In many men, effective suppression of spermatogenesis can be achieved by androgen-progestin combination therapy. Small-scale contraceptive efficacy studies in couples have demonstrated effectiveness and reversibility with male hormonal methods, but side effects related to mood, sexual desire and cholesterol remain concerning. A number of novel androgens have reached clinical testing as potential contraceptive agents; many of these have both androgenic and progestogenic action in a single, modified steroid, thereby holding promise as single-agent contraceptives. Currently, these novel steroids hold promise as both a "male pill" and long-acting injections. Among non-hormonal methods, studies of reversible vaso-occlusive methods (polymers that block transport of sperm through the vas deferens) are ongoing, but reliable reversibility and long-term safety in men have not been established. Proteins involved in sperm maturation and motility are attractive targets, but to date both specificity and biologic redundancy have been challenges for drug development. In this review, we aim to summarize landmark studies on male contraception, highlight the most recent advances and future development in this important field of public health and medicine.

PMID:
30588563
DOI:
10.1007/s40265-018-1038-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center